Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen

American Journal of Ophthalmology

Volumn 159, Issue 1, 2015, Pages 3-8.e1

  Rayess, Nadim ^a   Houston, S K Steven ^a   Gupta, Omesh P ^a   Ho, Allen C ^a   Regillo, Carl D ^a  

^a WILLS EYE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VISUAL ACUITY; CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MALE; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84920741399     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2014.09.011     Document Type: Article

References (19)

1. P.J. Rosenfeld, D.M. Brown, and J.S. Heier Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431
2. D.M. Brown, P.K. Kaiser, and M. Michels Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444
3. D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 7 2012 1388 1398
4. U. Chakravarthy, S.P. Harding, and C.A. Rogers Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 9900 2013 1258 1267
5. U. Schmidt-Erfurth, B. Eldem, and R. Guymer Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 118 5 2011 831 839
6. C.D. Regillo, D.M. Brown, and P. Abraham Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2 2008 239 248
7. A.E. Fung, G.A. Lalwani, and P.J. Rosenfeld An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 4 2007 566 583
8. G.A. Lalwani, P.J. Rosenfeld, and A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 1 2009 43 58 e1
9. O.P. Gupta, G. Shienbaum, A.H. Patel, C. Fecarotta, R.S. Kaiser, and C.D. Regillo A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact Ophthalmology 117 11 2010 2134 2140
10. R. Spaide Ranibizumab according to need: a treatment for age-related macular degeneration Am J Ophthalmol 143 4 2007 679 680
11. T.W. Stone 2013 Preferences and Trends (PAT) Survey 2013 American Society of Retina Specialists (ASRS) Toronto
12. G. Shienbaum, O.P. Gupta, C. Fecarotta, A.H. Patel, R.S. Kaiser, and C.D. Regillo Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact Am J Ophthalmol 153 3 2012 468 473 e1
13. M. Engelbert, S. Zweifel, and K.B. Freund Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy Retina 30 9 2010 1368 1375
14. M. Engelbert, S. Zweifel, and K.B. Freund "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation Retina 29 10 2009 1424 1431
15. F. Abedi, S. Wickremasinghe, A.F.M. Islam, K.M. Inglis, and R.H. Guymer Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years Retina 34 8 2014 1531 1538
16. N. Toalster, M. Russell, and P. Ng A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration Retina 33 7 2013 1351 1358
17. N.Z. Gregori, W. Feuer, and P.J. Rosenfeld Novel method for analyzing Snellen visual acuity measurements Retina 30 7 2010 1046 1050
18. J.P. Levine, I. Marcus, J.A. Sorenson, R.F. Spaide, M.J. Cooney, and K.B. Freund Macular hemorrhage in neovascular age-related macular degeneration after stabilization with antiangiogenic therapy Retina 29 8 2009 1074 1079
19. M. Singer, C.C. Awh, and S. Sadda HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration Ophthalmology 119 6 2012 1175 1183